CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group-Reference-Cited by-同舟云学术

CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group

Published:2011-10 Issue:11 Volume:12 Page:1013-1022
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Pfreundschuh Michael,Kuhnt Evelyn,Trümper Lorenz,Österborg Anders,Trneny Marek,Shepherd Lois,Gill Devinder S,Walewski Jan,Pettengell Ruth,Jaeger Ulrich,Zinzani Pier-Luigi,Shpilberg Ofer,Kvaloy Stein,de Nully Brown Peter,Stahel Rolf,Milpied Noel,López-Guillermo Armando,Poeschel Viola,Grass Sandra,Loeffler Markus,Murawski Niels

Publisher

Elsevier BV

Subject

Oncology

Reference18 articles.

1. A predictive model for aggressive non-Hodgkin's lymphoma;N Engl J Med,1993

2. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma;Coiffier;N Engl J Med,2002

3. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma;Habermann;J Clin Oncol,2006

4. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group;Pfreundschuh;Lancet Oncol,2006

5. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting—Airlie House, Virginia, November 1997;Harris;J Clin Oncol,1999

Cited by 600 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Navigating between Scylla and Charybdis: A roadmap to do better than Pola-RCHP in DLBCL;Cancer Treatment Reviews;2024-03

2. A nationwide analysis of the treatment patterns, survival, and medical costs in Korean patients with relapsed or refractory diffuse large B-cell lymphoma;Frontiers in Oncology;2024-02-01

3. Is oligometastatic disease an applicable and useful concept in haematologic malignancies? A narrative review of radiation therapy standards, modern techniques, and innovations;Cancer/Radiothérapie;2024-02

4. Comparison of Lugano Criteria Versus RECIL and PERCIST as Prognostic Factors in Diffuse Large B-Cell Lymphoma;Clinical Nuclear Medicine;2024-01-25

5. Long-term outcomes with HLX01 (HanliKang®), a rituximab biosimilar, in previously untreated patients with diffuse large B-cell lymphoma: 5-year follow-up results of the phase 3 HLX01-NHL03 study;BMC Cancer;2024-01-24